Cycle Pharmaceuticals Ltd press office | hosted by Press Dispensary

Cycle Pharmaceuticals Ltd logo - click for high-res version


Image library

This is a full set of images available. Click any image or image name for a higher resolution image (usually 300dpi). To download, use 'save' when viewing higher res image. (Tip: on a standard PC mouse, right-click for the save image command.)

Philippe Di Ruzza

Philippe Di Ruzza - click for high res image

Cycle Pharmaceuticals, North America Director
Click for higher resolution

Paula Bekinschtein

Paula Bekinschtein - click for high res image

Cycle Pharmaceuticals Global Marketing Manager
Click for higher resolution

INESSS makes first ever recommendation for HT-1 treatment

INESSS makes first ever recommendation for HT-1 treatment - click for high res image

Cycle Pharmaceutical’s Nitisinone Tablets becomes the first HT-1 treatment to pass through INESSS’ rigorous evaluation satisfying all therapeutic value criteria.
Click for higher resolution

Nitisinon-Produkt von Cycle Pharmaceuticals

Nitisinon-Produkt von Cycle Pharmaceuticals - click for high res image

Nitisinon-Produkt von Cycle Pharmaceuticals von Health Canada für die Behandlung von erblicher Tyrosinämie Typ 1 zugelassen
Click for higher resolution

Comprimidos de nitisinona da Cycle Pharmaceuticals

Comprimidos de nitisinona da Cycle Pharmaceuticals - click for high res image

Comprimidos de nitisinona da Cycle Pharmaceuticals são aprovados pelo Departamento de Saúde Pública do Canadá (Health Canada) no tratamento da Tirosinemia Hereditária Tipo 1
Click for higher resolution

Los comprimidos de nitisinona de Cycle Pharmaceuticals

Los comprimidos de nitisinona de Cycle Pharmaceuticals - click for high res image

Los comprimidos de nitisinona de Cycle Pharmaceuticals fueron aprobados por Health Canada (ministerio de salud de Canadá) para el tratamiento de la tirosinemia hereditaria tipo I.
Click for higher resolution

Approbation par Santé Canada des comprimés de nitisinone fabriqués par Cycle Pharmaceuticals pour le traitement de la tyrosinémie héréditaire de type 1

Approbation par Santé Canada des comprimés de nitisinone fabriqués par Cycle Pharmaceuticals pour le traitement de la tyrosinémie héréditaire de type 1  - click for high res image

Cycle Pharmaceuticals est heureux d’annoncer que ses comprimés de nitisinone ont reçu l’approbation de Santé Canada pour le traitement de la tyrosinémie héréditaire de type 1 (HT-1). Il s’agit du premier produit de nitisinone pouvant être entreposé à température ambiante à être approuvé dans le monde (la réfrigération n’est pas requise). Les comprimés de nitisinone produits par Cycle Pharmaceuticals ont également prouvé leur efficacité qu’ils soient pris pendant ou en-dehors des repas.
Click for higher resolution


About Cycle Pharmaceuticals Ltd

Pharmaceutical drug development

Cycle Pharmaceuticals is a Cambridge-based pharmaceutical company that optimises and increases access to existing pharmaceuticals. Specifically, Cycle focuses on three areas of pharmaceutical development:
• Improving orphan drugs, which treat the under-served rare disease patient community;
• Reinstating drug products that have been previously marketed;
• Working with our academic and other partners to extend pharmaceuticals to new medical areas where there is unmet need.
For further information on Cycle Pharmaceuticals, please visit http://www.cyclepharma.com.

For more information

Cycle Pharmaceuticals Ltd

Sonya Gade
project manager
Phone: + 44 (0) 1223 803 644
Email: sonya.gade@cyclepharma.com
Site: www.cyclepharma.com

RSS newsfeed:
http://www.pressdispensary.co.uk/
rssfeed/q991918/rss.xml